

Mycophenolate Mofetil-TL has an immunosuppressive effect. Selectively inhibits inosine monophosphate dehydrogenase and inhibits the synthesis of guanosine nucleotide. It has a pronounced cytostatic effect on lymphocytes, inhibits their proliferation, and inhibits the formation of antibodies by B-lymphocytes. When taken orally, it is rapidly absorbed and fully hydrolyzed, forming mycophenolic acid. Excreted mainly by the kidneys. In combination with azathioprine and cyclosporine, as well as with the induction course of antithymocyte globulin, reduces the incidence of adverse outcomes in the first 6 months after transplantation.
Prevention of the reaction of rejection and treatment of rejection of allogenic renal graft (in combination with cyclosporin A and glucocorticoids).
1 capsule contains:
Active substances: mycophenolate mofetil 500 mg.
Mycophenolate mofetil is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Mycophenolate Mofetil-TL | Drugs technology | Russia | pills |
Mycophenolate-Teva | Teva | Israel | capsules |
No customer reviews for the moment.
Applied as part of combination therapy with cyclosporine and corticosteroids. To prevent graft rejection, the first dose of mycophenolate mofetil is taken within the first 3 days after surgery. When taken orally, the recommended dose is 2 g per day, the frequency of reception - 2 times a day. For the treatment of rejection reactions - 3 g per day.
Nausea, vomiting, diarrhea, constipation, leukopenia or leukocytosis, anemia, thrombocytopenia, an increase in the frequency of infectious and septic complications; headaches, insomnia, tremor, fever, asthenia, lumbago, hypertension, cough, pharyngitis, dyspnea, peripheral edema, oropharyngeal candidiasis, hematuria, canalicular necrosis, impotence, acne, hyper- or hypocalymia, hyperglycemia, hypophosphate, hyperplasia, hypophosphate rash, pruritus.
Hypersensitivity, exacerbation of gastric ulcer and duodenal ulcer and other diseases of the gastrointestinal tract, pregnancy, breast-feeding, child age.
Probenecid and other drugs that affect tubular secretion, increase the plasma concentration of mycophenolic acid. Antacids containing hydroxides of magnesium and aluminum, reduce absorption. Drugs that alter the flora of the gastrointestinal tract, can disrupt the enterohepatic circulation. Reduces the effectiveness of oral contraception. Azathioprine increases the risk of developing lymphomas, especially skin.
It is necessary to take into account the possibility of increasing the risk of lymphoproliferative processes, regularly monitor the composition of peripheral blood, while reducing the number of neutrophils shows dose reduction or a break in treatment (and appropriate therapy). In the case of reducing the glomerular filtration rate below, it is not recommended to use more than 2 times a day. For more information, see the instructions for medical use of the drug.
Symptoms: an increase in the frequency of gastrointestinal and hematological (in particular neutropenia) side effects.
Treatment: dose reduction or drug withdrawal. To accelerate the excretion of possible sequestrants bile acids. Small amounts of glucuronide can be removed by hemodialysis (mycophenolic acid is not dialyzed).
Studies and clinical trials of Mycophenolate mofetil (Click to expand)